(2S)-3-氨基-2-(氨基羰基)-4-氧代-1-氮杂丁烷磺酸 | 86299-50-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S)-3-氨基-2-(氨基羰基)-4-氧代-1-氮杂丁烷磺酸
• 英文名称: (3S,4S)-3-amino-4-carbamoyl-2-azetidinone-1-sulfonic acid
• 英文别名: (3S,4S)-3-amino-4-carbamoyl-2-oxo-1-azetidinesulphonic acid；1-Azetidinesulfonic acid, 3-amino-2-(aminocarbonyl)-4-oxo-, (2S-cis)-；(2S,3S)-3-amino-2-carbamoyl-4-oxoazetidine-1-sulfonic acid
• CAS: 86299-50-5
• 化学式: C₄H₇N₃O₅S
• 分子量: 209.183
• InChiKey: CLGYPTDTSSKYIP-LWMBPPNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  152
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2S)-3-氨基-2-(氨基羰基)-4-氧代-1-氮杂丁烷磺酸 、 2-(2-chloroacetamidothiazol-4-yl)-(Z)-2-<1-methyl-1-(4-nitrobenzyloxycarbonyl)ethoxyimino>acetyl chloride hydrochloride 生成 (3S,4S)-3-<2-(2-aminothiazol-4-yl)-(Z)-2-(1-carboxy-1-methylethoxyimino)acetamido>-4-carbamoyl-2-azetidinone-1-sulfonic acid
  参考文献：
  名称：

  Synthesis of carumonam (AMA-1080) and a related compound starting from (2R,3R)-epoxysuccinic acid.

  摘要：

  在对磺胺氟噻嗪进行化学改造的过程中，合成了几种4-氨甲酰-2-氮杂环丁酮-1-磺酸衍生物，旨在提高其抗菌活性。在这些化合物中，(3S, 4S)-3-[2-(2-氨噻唑-4-基)-(Z)-2-(1-羧基-1-甲基乙氧亚胺)乙酰氨基]-4-氨甲酰-2-氮杂环丁酮-1-磺酸(2)被发现对抗革兰氏阴性细菌具有强大的抗菌活性，结果与卡鲁莫南(1, AMA-1080; Ro 17-2301)相当。基于(2R, 3R)-环氧琥珀酸(5)这一易于获取的发酵产物，开发了高效的合成路径，以大规模制备1和2。

  DOI：

  10.1248/cpb.33.3798
• 作为产物：
  描述：

  sodium (3S,4S)-benzyloxycarbonylamino-4-carbamoyl-2-azetidinone-1-sulfonate 在 palladium on activated charcoal 氢气 作用下， 以 水 为溶剂， 反应 0.67h， 生成 (2S)-3-氨基-2-(氨基羰基)-4-氧代-1-氮杂丁烷磺酸
  参考文献：
  名称：

  Synthesis of carumonam (AMA-1080) and a related compound starting from (2R,3R)-epoxysuccinic acid.

  摘要：

  在对磺胺氟噻嗪进行化学改造的过程中，合成了几种4-氨甲酰-2-氮杂环丁酮-1-磺酸衍生物，旨在提高其抗菌活性。在这些化合物中，(3S, 4S)-3-[2-(2-氨噻唑-4-基)-(Z)-2-(1-羧基-1-甲基乙氧亚胺)乙酰氨基]-4-氨甲酰-2-氮杂环丁酮-1-磺酸(2)被发现对抗革兰氏阴性细菌具有强大的抗菌活性，结果与卡鲁莫南(1, AMA-1080; Ro 17-2301)相当。基于(2R, 3R)-环氧琥珀酸(5)这一易于获取的发酵产物，开发了高效的合成路径，以大规模制备1和2。

  DOI：

  10.1248/cpb.33.3798

文献信息

• Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid
  申请人：Hoffmann-La Roche Inc.

  公开号：US04652651A1

  公开（公告）日：1987-03-24

  The manufacture of 1-sulpho-2-oxazetidine derivatives of the formula ##STR1## in which Het is an optionally amino-substituted, 5- or 6-membered, aromatic heterocycle containing 1 or 2 nitrogen atoms and optionally also an oxygen or sulphur atom, R.sup.1 is hydrogen, lower alkyl, phenyl-lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, phenyl-lower-alkoxycarbonyl-lower alkyl, nitrophenyl-lower-alkoxycarbonyl-lower alkyl or carboxy-lower alkyl and R.sup.2 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxycarbonyl, lower alkanoyloxy-lower alkyl, lower alkoxycarbonyl-lower alkenyl, hydroxyiminomethyl, lower alkoxyiminomethyl, carbamoyl, carbamoyl-lower alkenyl or carbamoyloxy-lower alkyl, the group .dbd.NOR.sup.1 being present at least partially in the syn-form, in racemic form or in the form of the 3S-enantiomer, and of readily hydrolyzable esters and pharmaceutically compatible salts of these compounds, by acylating a compound of the formula ##STR2## in which R.sup.20 equals R.sup.2 or can also represent a 2,2-dimethyl-1,3-dioxolan-4-yl group and R.sup.3 is hydrogen or sulpho, or a salt thereof with a thioester of the formula ##STR3## in which Het is as above and R.sup.10 has any of the values of R.sup.1 except carboxy-lower alkyl, and can also represent a tri-lower alkyl-silyl-lower-alkoxycarbonyl-lower alkyl group or a carboxy-lower alkyl group converted into a readily hydrolyzable ester group, and the group .dbd.NOR.sup.10 is present at least partially in the syn-form, and carrying out subsequent steps (N-sulphonation, conversion of R.sup.20 into R.sup.2, R.sup.10 into R.sup.1), some of which are optional. The invention also provides certain novel products of formula I and benzthiazolyl thioesters of formula III per se and the preparation of the benzthiazolyl thioesters by esterifying corresponding carboxylic acids. Finally, the invention provides a process for the preparation of carboxylic acids in which R.sup.1 is t-alkoxycarbonylmethyl. The compounds of formula I have antimicrobial activity.

  该专利描述了一种制备1-磺酸-2-噁唑环丙烷衍生物的方法，其化学式为##STR1##其中Het是一个含有1或2个氮原子和可能还有一个氧原子或硫原子的可选氨基取代的5或6元芳香杂环，R.sup.1是氢、低烷基、苯基-低烷基、低烷酰、低烷氧羰基、低烯基-低烷基、低烷氧羰基-低烷基、苯基-低烷氧羰基-低烷基、硝基苯基-低烷氧羰基-低烷基或羧基-低烷基，R.sup.2是氢、低烷基、低烯基、低炔基、低烷氧羰基、低烷酰氧基-低烷基、低烷氧羰基-低烯基、羟基亚胺甲基、低烷氧亚胺甲基、氨甲酰基、氨甲酰基-低烯基或氨甲酰氧基-低烷基，.dbd.NOR.sup.1基团至少部分以syn-形式存在，是外消旋形式或3S-对映体形式，以及这些化合物的易水解酯和药用兼容盐的制备方法。
• Antimicrobial 2-oxo-1-azetidinesulphonic acids
  申请人：Hoffmann-La Roche Inc.

  公开号：US04816582A1

  公开（公告）日：1989-03-28

  Antimicrobial 2-oxo-1-azetidinesulphonic acids of the formula ##STR1## in which H.sub.2 N ##STR2## represents an amino-substituted thiazolyl group, R.sup.1 is lower alkyl which is substituted by carbamoyl, lower alkylsuphonyl, azido, piperidine-carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl or lower alkynyl, and R.sup.2 is hydrogen or a lower organic group, typically, carbamoyloxymethyl.

  公式为##STR1##的抗微生物2-氧代-1-氮杂环丙磺酸，其中H.sub.2 N ##STR2##代表氨基取代的噻唑基团，R.sup.1是被氨甲酰基、低烷基磺酰基、叠氮基、哌啶基甲酰基、(六氢-1H-氮杂环庚烯-1-基)甲酰基或低烷基炔基取代的低烷基，R.sup.2是氢或低有机基，通常为氨甲酰氧甲基。
• Synthesis of carumonam (AMA-1080) and a related compound starting from (2R,3R)-epoxysuccinic acid.
  作者：MICHIYUKI SENDAI、SHOHEI HASHIGUCHI、MITSUMI TOMIMOTO、SHOJI KISHIMOTO、TAISUKE MATSUO、MICHIHIKO OCHIAI

  DOI：10.1248/cpb.33.3798

  日期：——

  In the course of the chemical modification of sulfazecin, several 4-carbamoyl-2-azetidinone-1-sulfonic acid derivatives were synthesized with the aim of improving the antibacterial activity. Among those compounds, (3S, 4S)-3-[2-(2-aminothiazol-4-yl)-(Z)-2-(1-carboxy-1-methylethoxyimino) acetamido]-4-carbamoyl-2-azetidinone-1-sulfonic acid (2) was found to have potent antibacterial activity, comparable to that of carumonam (1, AMA-1080 ; Ro 17-2301), against gramnegative bacteria. Efficient synthetic pathways to prepare 1 and 2 in large quantities were developed based on (2R, 3R)-epoxysuccinic acid (5), an easily accessible fermentation product, as a starting chiral synthon.

  在对磺胺氟噻嗪进行化学改造的过程中，合成了几种4-氨甲酰-2-氮杂环丁酮-1-磺酸衍生物，旨在提高其抗菌活性。在这些化合物中，(3S, 4S)-3-[2-(2-氨噻唑-4-基)-(Z)-2-(1-羧基-1-甲基乙氧亚胺)乙酰氨基]-4-氨甲酰-2-氮杂环丁酮-1-磺酸(2)被发现对抗革兰氏阴性细菌具有强大的抗菌活性，结果与卡鲁莫南(1, AMA-1080; Ro 17-2301)相当。基于(2R, 3R)-环氧琥珀酸(5)这一易于获取的发酵产物，开发了高效的合成路径，以大规模制备1和2。